Cargando…
Sodium‐glucose co‐transporter 2 inhibitor therapy: use in chronic kidney disease and adjunctive sodium restriction
The global burden of chronic kidney disease (CKD) has increased significantly over the past few decades. This reflects the rising prevalence of type 2 diabetes mellitus (T2DM) and hypertension, two leading causes of CKD. Hypertension, which can also be a complication of CKD, accelerates renal diseas...
Autores principales: | Tiwary, Mansi, Milder, Tamara Y., Stocker, Sophie L., Day, Richard O., Greenfield, Jerry R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796501/ https://www.ncbi.nlm.nih.gov/pubmed/35257458 http://dx.doi.org/10.1111/imj.15727 |
Ejemplares similares
-
Potential Safety Issues with Use of Sodium-Glucose Cotransporter 2 Inhibitors, Particularly in People with Type 2 Diabetes and Chronic Kidney Disease
por: Milder, Tamara Y., et al.
Publicado: (2020) -
Sodium-Glucose Linked Transporter-2 Inhibitors in Chronic Kidney Disease
por: Zanoli, L., et al.
Publicado: (2015) -
Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney Function
por: Van Raalte, Daniel H., et al.
Publicado: (2022) -
Emerging Role of Sodium–Glucose Co-Transporter 2 Inhibitors for the Treatment of Chronic Kidney Disease
por: Isidto, Rey, et al.
Publicado: (2023) -
Role of sodium‐glucose transporters in glucose uptake of the intestine and kidney
por: Harada, Norio, et al.
Publicado: (2012)